%0 Journal Article
%T Mobilization of hematopoietic progenitor cells with granulocyte colony stimulating factors for autologous transplant in hematologic malignancies: a single center experience
%A Gab¨²s
%A Raul
%A Borelli
%A Gabriel
%A Ferrando
%A Mart¨ªn
%A B¨®dega
%A Enrique
%A Citr¨ªn
%A Estela
%A Olivera Jim¨¦nez
%A Constanza
%A ¨¢lvarez
%A Ram¨®n
%J Revista Brasileira de Hematologia e Hemoterapia
%D 2011
%I Sociedade Brasileira de Hematologia e Hemoterapia
%R 10.5581/1516-8484.20110115
%X background: in 2006 the hematology service of hospital maciel published its experience with peripheral blood progenitor cell harvesting for autologous stem cell transplantation using filgen jp (clausen filgrastim). after mobilization with a mean filgrastim dose of 78 mcg/kg, 4.7 x 106 cd34+ cells/kg were obtained by apheresis. age above 50, multiple myeloma as underlying disease and a malignancy that was not in remission were identified as frequent characteristics among patients showing complex mobilization. objective: the aim of this study was to compare stem cell mobilization using different brands of filgrastim. methods: one hundred and fifty-seven mobilizations performed between 1997 and 2006 were analyzed. this retrospective analysis comparative two groups of patients: those mobilized with different brands of filgrastim (group a) and those who received filgen jp (clausen filgrastim) as mobilizing agent (group b). a cluster analysis technique was used to identify four clusters of individuals with different behaviors differentiated by age, total dose of filgrastim required, number of apheresis and harvested cd34+ cells. results: the mean total dose of filgrastim administered was 105 mcg/kg, the median number of apheresis was 2 procedures and the mean number of harvested stem cells was 4.98 x 106 cd34+ cells/kg. no significant differences were observed between groups a and b regarding the number of apheresis, harvested cd34+ cells and number of mobilization failures, however the total dose of filgrastim was significantly lower in group b. conclusions: among other factors, the origin of the cytokine used as mobilizing agent is an element to be considered when evaluating cd34+ cell mobilization results.
%K filgrastim
%K hematopoietic stem cell mobilization
%K blood component removal.
%U http://www.scielo.br/scielo.php?script=sci_abstract&pid=S1516-84842011000600008&lng=en&nrm=iso&tlng=en